Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 895 of 5804
-
New hope for young kidney transplant patients: safer drug combo tested
Disease control Recruiting nowThis is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours followin…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Magnetic pulses may rewire brain connections in schizophrenia
Disease control Recruiting nowPatients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.
Phase: NA • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could skipping surgery be safe for some rectal cancer patients?
Disease control Recruiting nowThe goal of this one-arm clinical trial is to implement and study the oncological outcomes of nonoperative management of rectal cancer having complete clinical response to neoadjuvant therapy. The main questions to answer are * if the oncological results of nonoperative manageme…
Phase: NA • Sponsor: Tampere University Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:14 UTC
-
Gene therapy for gaucher disease: 5-year safety check begins
Disease control OngoingThis is a multicenter, long-term, follow-up trial of participants with Gaucher disease type 1 who received FLT201 treatment in a preceding clinical trial. Participants will be followed for 5 years post-treatment.
Phase: PHASE1, PHASE2 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Dissolving stent could change heart disease treatment
Disease control OngoingThe objective of this study is to assess the safety and efficacy of the Freesolve in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to a contemporary drug eluting stent (DES).
Phase: NA • Sponsor: Biotronik AG • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for aHUS patients: Long-Term iptacopan study launches
Disease control Recruiting nowThis is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could this pill tame rare immune tumors?
Disease control Recruiting nowThe researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Does surgery for hip tendon tears actually work? a Sham-Controlled trial aims to find out
Disease control TerminatedThis study will examine the effectiveness of open surgical reconstruction in the treatment of patients with hip abductor tendon tears. Patients will be randomly allocated to either the open surgical reconstruction or to a open surgical sham procedure. The primary outcome is patie…
Phase: NA • Sponsor: Horsens Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cheaper keytruda alternative tested in lung cancer trial
Disease control CompletedThe purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status), without sensitizing EGFR or ALK mutations.
Phase: PHASE3 • Sponsor: Sandoz • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Heart device infection? new study tests immediate replacement
Disease control Recruiting nowThe goal of this randomized clinical trials is to ascertain the safety and efficacy of immediate reimplantation of cardiac electronic implantable devices in patients with endocarditis and device-infections, compared to standard care, i.e. reimplantation at a later procedure date.…
Phase: PHASE3 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Brain scans may reveal why behavioral therapy helps some teens with tics
Symptom relief Recruiting nowTourette Syndrome and Persistent Motor/Vocal Tic Disorder affect 1-3% of youth and can be associated with impaired functioning, emotional and behavioral problems, physical pain, diminished quality of life, and peer victimization. Chronic tics are the primary symptom. Comprehensiv…
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
New cocktail of four chemo drugs shows promise for tough pancreatic cancer
Disease control CompletedThis study is to assess the anti-tumour activity, safety and tolerability of irinotecan liposome injection (S095013) in combination with oxaliplatin, 5-Fluorouracil (5-FU) and levoisomer form of leucovorin (LLV). S095013, oxaliplatin, 5-FU and LLV will be administered on days 1 a…
Phase: PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Weight-Loss drug semaglutide may help smokers avoid Post-Quit pounds
Disease control Recruiting nowThis trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New mRNA bird flu vaccine shows promise in early trials
⭐️ VACCINE ⭐️ CompletedThe aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:02 UTC
-
One-Hour brain infection test could save lives
Diagnosis CompletedInfections involving the central nervous system (CNS), such as meningitis/encephalitis (ME), are serious clinical conditions associated with high morbidity and mortality rates, as well as significant long-term consequences. ME can be caused by a wide variety of pathogenic agents.…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Weekly shot shows promise for diabetes control in major trial
Disease control CompletedThis is a randomized, double-blind, placebo-parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.
Phase: PHASE3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Gene therapy for HAE: does it last? new study tracks Long-Term safety
Disease control ENROLLING_BY_INVITATIONThis is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New shot aims to stop the itch of prurigo nodularis
Symptom relief OngoingThe purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New pill xanamem aims to slow Alzheimer's decline
Disease control OngoingXanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia d…
Phase: PHASE2, PHASE3 • Sponsor: Actinogen Medical • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug cocktails aim to beat river blindness
Disease control OngoingThis study will investigate the safety and effectiveness of combination regimens in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and eyes.
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC